Sugi Predict

Sugi Predict / Compounds / SCHEMBL1904067

SCHEMBL1904067

SCHEMBL1904067

CC(=O)Nc1c[c]ccn1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ PTK2 Q05397 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ PIK3C3 Q8NEB9 6/20 0.38
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ TYK2 P29597 1/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ MAPK8 P45983 1/20 0.36
▸ KMT2A Q03164 1/20 0.35
▸ GLS O94925 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15192019 0.80 ALDH1A1 (0.41) KDM4ETYK2LMNAMAPK8KMT2A
SCHEMBL9513759 0.76 KMT2A (0.48) L3MBTL1KDM4EPIK3C3CYP1A2GAA
SCHEMBL6950030 0.76 ATR (0.41) —
SCHEMBL15322822 0.75 L3MBTL1 (0.48) L3MBTL1PTK2KDM4EHSP90AA1HSP90AB1
SCHEMBL8415569 0.73 L3MBTL1 (0.53) L3MBTL1KDM4ECYP1A2GAALMNA
SCHEMBL7220284 0.73 — —
SCHEMBL358262 0.73 — —
SCHEMBL1751921 0.72 — —
SCHEMBL7221398 0.70 TP53 (0.36) KDM4EGAA
SCHEMBL7013319 0.70 MEN1 (0.42) L3MBTL1KDM4ELMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10787444-B2 Compounds for the modulation of myc activity SYROS PHARMACEUTICALS, INC. (US) 2020-09-29 — — US claimed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 — — US claimed
WO-2016197078-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS, INC. (US) 2016-12-08 — — WO claimed
US-20140128373-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2014-05-08 — — US claimed
CN-103517710-A Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC 2014-01-15 — — CN claimed
EP-2672967-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Plexxikon, Inc. (US) 2013-12-18 — — EP claimed
WO-2012109075-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2012-08-16 — — WO claimed
US-20100227858-A1 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES ASTRAZENECA AB (SE) 2010-09-09 — — US claimed
EP-2176256-A2 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES AstraZeneca AB (SE) 2010-04-21 — — EP claimed
WO-2009007751-A2 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES ASTRAZENECA AB (SE) 2009-01-15 — — WO claimed
US-5776954-A GLUCAGON ANTAGONISTS MERCK & CO., INC. (US) 1998-07-07 — — US claimed
CN-111886227-B Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions containing them 柳韩洋行 2023-10-13 — — CN disclosed
CN-116802184-A Pyrazolothiazole carboxamides and their use as PDGFR inhibitors 埃科特莱茵药品有限公司 2023-09-22 — — CN disclosed
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2023-09-07 — — US disclosed
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 — — US disclosed
WO-1997036905-A1 DIAZEPINO-INDOLES AS PHOSPHODIESTERASE IV INHIBITORS INSTITUT DE RECHERCHE JOUVEINAL (FR) 1997-10-09 — — WO disclosed
WO-1997016442-A1 SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 1997-05-09 — — WO disclosed
EP-0269859-B2 Pyrazolotriazine compounds OTSUKA PHARMA CO LTD (JP) 1995-10-18 — — EP disclosed
US-4824834-A TREATING GOUT OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1989-04-25 — — US disclosed
EP-0269859-A2 Pyrazolotriazine compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-06-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 L3MBTL1 2794/4885PTK2 1817/4885KDM4E 4565/4885
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 L3MBTL1 861/4885PTK2 120/4885KDM4E 2174/4885
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 L3MBTL1 3153/4885PTK2 1224/4885KDM4E 4623/4885
US-10787444-B2 Compounds for the modulation of myc activity MYC, MYCBP, MYCBP2 L3MBTL1 2794/4885PTK2 1817/4885KDM4E 4565/4885
US-20140128373-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 L3MBTL1 861/4885PTK2 120/4885KDM4E 2174/4885
US-20100227858-A1 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES MTOR, PIK3CA, PIK3CD L3MBTL1 4396/4885PTK2 253/4885KDM4E 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.